ERVW-1 and myeloid sarcoma: The HERV-W ENV protein has been recognized as an MS-specific pathogenic entity, and functional evidence of its anti-regenerative/remyelinating properties has recently been collected in a clinical trial using the neutralizing antibody GNbAC1/Temelimab (Hartung et al., 2021).